Literature DB >> 15341682

Clinical trials report. Adverse prognostic significance of new diabetes in treated hypertensive subjects.

Norman M Kaplan1.   

Abstract

Entities:  

Year:  2004        PMID： 15341682     DOI： 10.1007/s11906-004-0050-4

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  11 in total

1.  Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor.

Authors:  G Wolf; F N Ziyadeh; F Thaiss; J Tomaszewski; R J Caron; U Wenzel; G Zahner; U Helmchen; R A Stahl
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 2.  Metabolic effects of antihypertensive treatment: long live the debate.

Authors:  Ele Ferrannini; Michaela Kozàkovà
Journal:  J Hypertens       Date:  2003-08       Impact factor: 4.844

3.  When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk.

Authors:  George L Bakris; James R Sowers
Journal:  Hypertension       Date:  2004-03-22       Impact factor: 10.190

4.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

5.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

Authors:  T W Gress; F J Nieto; E Shahar; M R Wofford; F L Brancati
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

6.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Authors:  Naoyuki Nakao; Ashio Yoshimura; Hiroyuki Morita; Masyuki Takada; Tsuguo Kayano; Terukuni Ideura
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

7.  Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

Authors:  Lars H Lindholm; Mats Persson; Petar Alaupovic; Bo Carlberg; Anders Svensson; Ola Samuelsson
Journal:  J Hypertens       Date:  2003-08       Impact factor: 4.844

8.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

9.  Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.

Authors:  Bruce M Psaty; Thomas Lumley; Curt D Furberg; Gina Schellenbaum; Marco Pahor; Michael H Alderman; Noel S Weiss
Journal:  JAMA       Date:  2003-05-21       Impact factor: 56.272

10.  Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury.

Authors:  Zemin Cao; Fabrice Bonnet; Riccardo Candido; Stefan P Nesteroff; Wendy C Burns; Hiroshi Kawachi; Fujio Shimizu; Robert M Carey; Marc De Gasparo; Mark E Cooper
Journal:  J Am Soc Nephrol       Date:  2002-07       Impact factor: 10.121
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.